AbbVie Shares Sold by Trust Co. of Vermont

Institutional investor reduces stake in pharmaceutical company

Apr. 2, 2026 at 11:49am

Got story updates? Submit your updates here. ›

Trust Co. of Vermont, a financial services firm, reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the fourth quarter, according to a recent SEC filing. The firm now owns 168,625 shares of the pharmaceutical company's stock, valued at $38.5 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio, so changes in institutional ownership of its stock can provide insights into investor sentiment and market trends within the healthcare sector.

The details

According to the filing, Trust Co. of Vermont sold 5,899 shares of AbbVie during the fourth quarter. The firm's total holdings in AbbVie now account for 1.6% of its investment portfolio, making it the 12th largest position. Several other large investors also adjusted their AbbVie positions during the quarter, with some increasing and others decreasing their stakes.

  • The share sale occurred in the fourth quarter of 2026.

The players

Trust Co. of Vermont

A financial services firm that reduced its holdings in AbbVie Inc. by 3.4% in the fourth quarter.

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Trust Co. of Vermont's AbbVie holdings suggests some institutional investors may be taking a more cautious stance on the pharmaceutical company's stock, even as others maintain or increase their positions. This could signal a broader shift in market sentiment around AbbVie and the healthcare sector.